Clinical Commander

Back to dossier
cardio.cardiogenic-shock.anthracycline-cardiotoxicity.v1PRODUCTION
cardio.cardiogenic-shock.anthracycline-cardiotoxicity.v1

Cardiogenic shock — anthracycline-induced cardiomyopathy with shock physiology

cardiologyacuteadult
Hard-required inputs
0 / 14
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm anthracycline-CMP as the shock etiology — cumulative dose history + diffuse global LV dysfunction + no obstructive CAD pattern; assess concurrent cardiotoxic factors (trastuzumab, thoracic radiation); cancer status (remission vs active) shapes long-term decisions

Inputs
4
Actions
0
Advance rule
Set
Advance when

Anthracycline-CMP with shock confirmed and cumulative-dose risk-tier assigned

Patient inputs (15)

Mandatory rule-out of obstructive CAD when shock + LV dysfunction (anthracycline-CMP can mimic AMI); thoracic-radiation patients have premature CAD risk

Older patients (>65) higher cardiotoxicity risk; informs prognosis + transplant candidacy

Doxorubicin >450 mg/m² or equivalent — primary risk factor; informs continuation decision and risk-stratifies recovery probability

Synergistic cardiotoxicity drivers; modifies treatment + prognosis

Disease-free status determines transplant eligibility (typically ≥5 yr for solid tumors per ISHLT 2016 historical; case-by-case modern); active malignancy modifies aggressiveness of CV care

Tachycardia common in CS; bradyarrhythmia in advanced HF; AV block possible in cumulative anthracycline

End-organ damage marker; eGFR for ARNI / SGLT2i / ACEi / contrast / gadolinium dosing

High-sensitivity troponin — early subclinical injury marker per Cardinale Circulation 2004 PMID 15067104

Acute HF marker; trend tracks recovery during cardioprotective therapy

Cancer treatment cytopenia surveillance; baseline for ongoing cancer care decisions

LVEF + GLS — primary diagnostic + surveillance modality per ESC 2022 + Plana JASE 2014; diffuse global pattern (not single coronary territory)

Sinus tachycardia, low voltage, non-specific ST/T changes; conduction abnormalities possible in cumulative dose

SCAI 2022 staging baseline; gates vasopressor escalation

SCAI 2022 staging + CardShock prognostication (Harjola EHJ 2015 PMID 26333869)

LVEF + diffuse mid-wall LGE pattern; T1 mapping for diffuse fibrosis; rules out alternative cardiomyopathies; prognostic for recovery

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningtransplant_eligibility_evaluation_despite_cancer_history
    Refractory severe LV dysfunction with refractory shock in anthracycline-CMP — transplant evaluation despite cancer history; historical ISHLT 2016 disease-free interval ≥5 yr for solid tumors / ≥1 yr for hematologic being relaxed; case-by-case per modern criteria with cardio-onc + transplant + oncology MDT
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningventricular_electrical_storm_in_dilated_anthracycline_cmp
    Sustained VT/VF or recurrent shocks within 24 h in dilated anthracycline-CMP — high arrhythmia risk in dilated chamber substrate; amiodarone + EP + escalate to MCS; ICD evaluation if cancer-prognosis permits
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecumulative_anthracycline_dose_threshold_reached_with_lv_dysfunction
    Cumulative doxorubicin >450 mg/m² (or daunorubicin >550, epirubicin >900) + new LVEF decline ≥10 absolute or to <50% — anthracycline cardiotoxicity confirmed; emergent oncology + cardio-onc decision to discontinue further anthracycline; consider dexrazoxane only if continued anthracycline benefit per FDA label (metastatic breast cancer)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatedexrazoxane_decision_in_continued_anthracycline_metastatic_breast_cancer
    Metastatic breast cancer patient receiving cumulative doxorubicin ≥300 mg/m² who would benefit from continued anthracycline therapy per oncology — dexrazoxane FDA-approved indication; cardio-oncology + oncology joint decision
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecovery_and_cancer_continuation_balance
    Partial LV recovery achieved on GDMT — oncology decision on continued cancer therapy: switch to non-cardiotoxic regimen if cancer permits; if anthracycline benefit unmistakable per oncology, dexrazoxane FDA-label consideration; surveillance echo + GLS per ESC 2022 cardio-onc protocol
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Anthracycline-CMP cardiogenic shock — supportive + GDMT 4-pillar cardioprotection per Cardinale 2015 + early MCS bridge to recovery + cancer-treatment continuation balance
axis: anthracycline_cmp_cs_phenotype
Selected axis "Anthracycline-CMP cardiogenic shock — supportive + GDMT 4-pillar cardioprotection per Cardinale 2015 + early MCS bridge to recovery + cancer-treatment continuation balance" by default fallback (first axis)
  • norepinephrine
    first line
    vasopressor_alpha
    0.05–0.5 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: anthracycline_cmp_with_sbp_lt_90, cs_scai_c_or_higher
    SOAP-II PMID 20200382 — NE first-line in CS
    rxcui 7512
  • dobutamine
    second line
    inotrope_beta1
    2.5 µg/kg/min cautious titration • IV • continuous
    triggers: low_cardiac_output_despite_NE, no_active_VT_or_VF
    DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in dilated anthracycline myopathy given arrhythmia substrate
    rxcui 3616
  • carvedilol
    first line
    beta_blocker_nonselective_alpha1
    3.125 mg PO BID; titrate q2 wk to 25 mg BID (50 mg BID if >85 kg) • PO • BID
    triggers: anthracycline_cmp_off_catecholamines_24h, persistent_ef_lt_40_after_recovery
    Cardinale 2015 PMID 25956652 — carvedilol + enalapril partial recovery in 64% of anthracycline-CMP within 6 mo of cardiotoxicity onset; AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499); preferred β-blocker in cardio-onc per ESC 2022 (PMID 36017575) given antioxidant property
    rxcui 20352
  • sacubitril-valsartan
    first line
    arni
    24/26 BID start; titrate to 97/103 BID • PO • BID
    triggers: anthracycline_cmp_persistent_ef_lt_40, sbp_ge_100, egfr_ge_30, no_recent_acei_within_36h
    PARADIGM-HF PMID 25176015 — ARNI superior to ACEi in HFrEF; reasonable extrapolation to anthracycline-CMP per ESC 2022 cardio-oncology
    rxcui 1656328
  • lisinopril
    first line
    acei
    2.5–5 mg daily; titrate to 20–40 mg daily • PO • daily
    triggers: anthracycline_cmp_arni_intolerant, cardioprotection_during_anthracycline_therapy
    Cardinale 2015 PMID 25956652 — enalapril prevented further LV decline + drove partial recovery in 64%; PRADA trial (Heck JAMA Cardiol 2021) — candesartan/metoprolol prevented LVEF decline during anthracycline therapy
    rxcui 29046
  • spironolactone
    first line
    mineralocorticoid_receptor_antagonist
    25 mg daily • PO • daily
    triggers: persistent_ef_lt_40, k_lt_5, egfr_ge_30
    RALES PMID 10471456 — spironolactone in HFrEF; AHA/ACC/HFSA 2022 HF Guideline class I
    rxcui 9997
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg daily • PO • daily
    triggers: persistent_ef_lt_40, egfr_ge_20
    EMPEROR-Reduced PMID 32865377; HOMER trial ongoing for anthracycline-CMP specifically; ESC 2022 cardio-oncology supports SGLT2i in HFrEF post-cardiotoxicity
    rxcui 1545653
  • dapagliflozin
    first line
    sglt2_inhibitor
    10 mg daily • PO • daily
    triggers: persistent_ef_lt_40, egfr_ge_20, empagliflozin_unavailable
    DAPA-HF PMID 31535829 — dapagliflozin alternative SGLT2i in HFrEF
    rxcui 1488564
  • amiodarone
    rescue
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min • IV • continuous
    triggers: ventricular_electrical_storm_in_dilated_anthracycline_cmp, sustained_vt_or_vf
    AHA 2020 ACLS Class IIb for refractory VT/VF; relevant in dilated anthracycline-CMP arrhythmia substrate
    rxcui 703
  • dexrazoxane
    comorbidity specific
    iron_chelator_cardioprotectant
    10:1 ratio with doxorubicin (10 mg dexrazoxane per 1 mg doxorubicin) IV pre-anthracycline • IV • pre-each anthracycline cycle
    triggers: continued_anthracycline_required_with_cumulative_dose_at_threshold, metastatic_breast_cancer_doxorubicin_above_300_per_fda_label
    Swain JCO 1997 PMID 9263800 — FDA-approved cardioprotectant for metastatic breast cancer patients receiving cumulative doxorubicin ≥300 mg/m² who would benefit from continued anthracycline; ESC 2022 cardio-oncology + AHA 2022 cardio-oncology recognize indication
    rxcui 1294534
  • DISCONTINUE further anthracycline
    contraindication substitute
    oncology_coordination
    Oncology + cardio-onc joint decision — switch to non-cardiotoxic regimen (taxane, capecitabine, immunotherapy per cancer type) • n/a • n/a
    triggers: anthracycline_cmp_with_shock_physiology, symptomatic_lvef_decline_during_therapy
    ESC 2022 cardio-oncology PMID 36017575 — discontinuation of cardiotoxic agent is the cornerstone; oncology may switch to non-cardiotoxic regimen per cancer type

outpatient playbook — drug actions (3)

  1. 1. continue or up-titrate GDMT 4-pillar if persistent EF<40
    sac/val + carvedilol + MRA + SGLT2i • PO • daily/BID
    trigger: Persistent EF<40
    AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499); Cardinale 2015 PMID 25956652 partial recovery in 64%
  2. 2. AVOID further anthracycline if recovery achieved
    oncology + cardio-onc joint decision • n/a • n/a
    trigger: History of anthracycline-CMP + cancer remission
    ESC 2022 cardio-oncology PMID 36017575 — re-exposure substantially increases recurrence risk
  3. 3. dexrazoxane consideration if continued anthracycline benefit per FDA label
    rxcui 42736
    10:1 ratio with doxorubicin IV pre-cycle • IV • pre-each anthracycline cycle
    trigger: Metastatic breast cancer + cumulative doxorubicin ≥300 mg/m² + continued anthracycline benefit
    Swain JCO 1997 PMID 9263800 — FDA-approved cardioprotectant indication

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Cumulative doxorubicin >450 mg/m² (or equivalent — daunorubicin >550, epirubicin >900) + acute LV dysfunction + shock physiology → anthracycline-CMP with CS; Concurrent / sequential anthracycline + trastuzumab + acute LV dysfunction with hypoperfusion → additive cardiotoxicity per Slamon 2001 PMID 11248153; Severe global LV dysfunction (EF <30) with diffuse pattern (not single coronary territory) on echo + GLS markedly reduced + recent anthracycline exposure.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — anthracycline-induced cardiomyopathy with shock physiology** (cardio.cardiogenic-shock.anthracycline-cardiotoxicity.v1).
Scope: Confirm anthracycline-CMP as the shock etiology — cumulative dose history + diffuse global LV dysfunction + no obstructive CAD pattern; assess concurrent cardiotoxic factors (trastuzumab, thoracic radiation); cancer status (remission vs active) shapes long-term decisions

No severity triggers fired against current inputs.

Plan

Regimen axis: **Anthracycline-CMP cardiogenic shock — supportive + GDMT 4-pillar cardioprotection per Cardinale 2015 + early MCS bridge to recovery + cancer-treatment continuation balance**.
1. norepinephrine 0.05–0.5 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS
2. dobutamine 2.5 µg/kg/min cautious titration IV continuous (inotrope_beta1, second line) — DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in dilated anthracycline myopathy given arrhythmia substrate
3. carvedilol 3.125 mg PO BID; titrate q2 wk to 25 mg BID (50 mg BID if >85 kg) PO BID (beta_blocker_nonselective_alpha1, first line) — Cardinale 2015 PMID 25956652 — carvedilol + enalapril partial recovery in 64% of anthracycline-CMP within 6 mo of cardiotoxicity onset; AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499); preferred β-blocker in cardio-onc per ESC 2022 (PMID 36017575) given antioxidant property
4. sacubitril-valsartan 24/26 BID start; titrate to 97/103 BID PO BID (arni, first line) — PARADIGM-HF PMID 25176015 — ARNI superior to ACEi in HFrEF; reasonable extrapolation to anthracycline-CMP per ESC 2022 cardio-oncology
5. lisinopril 2.5–5 mg daily; titrate to 20–40 mg daily PO daily (acei, first line) — Cardinale 2015 PMID 25956652 — enalapril prevented further LV decline + drove partial recovery in 64%; PRADA trial (Heck JAMA Cardiol 2021) — candesartan/metoprolol prevented LVEF decline during anthracycline therapy
6. spironolactone 25 mg daily PO daily (mineralocorticoid_receptor_antagonist, first line) — RALES PMID 10471456 — spironolactone in HFrEF; AHA/ACC/HFSA 2022 HF Guideline class I
7. empagliflozin 10 mg daily PO daily (sglt2_inhibitor, first line) — EMPEROR-Reduced PMID 32865377; HOMER trial ongoing for anthracycline-CMP specifically; ESC 2022 cardio-oncology supports SGLT2i in HFrEF post-cardiotoxicity
8. dapagliflozin 10 mg daily PO daily (sglt2_inhibitor, first line) — DAPA-HF PMID 31535829 — dapagliflozin alternative SGLT2i in HFrEF
9. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min IV continuous (class_iii_antiarrhythmic, rescue) — AHA 2020 ACLS Class IIb for refractory VT/VF; relevant in dilated anthracycline-CMP arrhythmia substrate
10. dexrazoxane 10:1 ratio with doxorubicin (10 mg dexrazoxane per 1 mg doxorubicin) IV pre-anthracycline IV pre-each anthracycline cycle (iron_chelator_cardioprotectant, comorbidity specific) — Swain JCO 1997 PMID 9263800 — FDA-approved cardioprotectant for metastatic breast cancer patients receiving cumulative doxorubicin ≥300 mg/m² who would benefit from continued anthracycline; ESC 2022 cardio-oncology + AHA 2022 cardio-oncology recognize indication
11. DISCONTINUE further anthracycline Oncology + cardio-onc joint decision — switch to non-cardiotoxic regimen (taxane, capecitabine, immunotherapy per cancer type) n/a n/a (oncology_coordination, contraindication substitute) — ESC 2022 cardio-oncology PMID 36017575 — discontinuation of cardiotoxic agent is the cornerstone; oncology may switch to non-cardiotoxic regimen per cancer type

Setting playbook (outpatient) — 4–8 wk recovery echo + GLS — confirm LV recovery (partial recovery 40–60% per Cardinale 2015); long-term GDMT 4-pillar; long-term cardio-oncology surveillance (annual echo + GLS); ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting; transplant evaluation if persistent severe LV dysfunction + cancer disease-free per modern criteria; oncology coordination for ongoing cancer surveillance + dexrazoxane consideration if continued anthracycline required per FDA label
12. continue or up-titrate GDMT 4-pillar if persistent EF<40 sac/val + carvedilol + MRA + SGLT2i PO daily/BID — Persistent EF<40 (AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499); Cardinale 2015 PMID 25956652 partial recovery in 64%)
13. AVOID further anthracycline if recovery achieved oncology + cardio-onc joint decision n/a n/a — History of anthracycline-CMP + cancer remission (ESC 2022 cardio-oncology PMID 36017575 — re-exposure substantially increases recurrence risk)
14. dexrazoxane consideration if continued anthracycline benefit per FDA label 10:1 ratio with doxorubicin IV pre-cycle IV pre-each anthracycline cycle — Metastatic breast cancer + cumulative doxorubicin ≥300 mg/m² + continued anthracycline benefit (Swain JCO 1997 PMID 9263800 — FDA-approved cardioprotectant indication)

Non-pharmacologic actions:
- No competitive sports for 3-6 mo per AHA / ESC sports cardiology
- Cardiac rehab if persistent LV dysfunction
- EP referral for ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting
- Transplant evaluation if persistent severe LV dysfunction + cancer disease-free per modern criteria (case-by-case)
- Long-term cardio-oncology surveillance (annual echo + GLS + CV risk assessment per ESC 2022)

AVOID / contraindication checks:
- Nsaids_AVOID_in_hfref (worsens HF + AKI)
- Digoxin_caution_in_dilated_cardiomyopathy_with_arrhythmia_substrate (toxicity threshold)
- Gadolinium_caution_if_egfr_lt_30 (NSF risk; group II macrocyclic agents safer)
- Arni_avoid_pregnancy (teratogenic — cancer survivor age varies)
- Sglt2i_caution_dka_risk_in_diabetic_cancer_patients_with_low_oral_intake
- Contrast_minimize_in_anthracycline_cmp_with_aki (use ultrasound / CMR alternatives where feasible)
- Trastuzumab_hold_during_lvef_decline (additive cardiotoxicity per Slamon NEJM 2001 + Tan Chiu)
- Dexrazoxane_indication_limited_to_fda_label (metastatic breast cancer doxorubicin ≥300 mg/m²)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q24h with lvef and gls for recovery trajectory (Plana JASE 2014 + ESC 2022)
- continuous telemetry for arrhythmia (dilated cardiomyopathy substrate)
- daily troponin and bnp (recovery tracking)
- cmr at 4-8 weeks for lge burden and recovery assessment
- baseline and serial gls during any continued oncology therapy (ESC 2022 cardio-oncology)

Setting (outpatient) monitoring:
- Echo + GLS at 6 mo and 12 mo, then annually per ESC 2022 cardio-onc
- CMR at 6 mo if persistent LGE for arrhythmic risk surveillance

Follow-up plan: Repeat echo + GLS at 4–8 wks for recovery trajectory; CMR at 4–8 wks; long-term GDMT 4-pillar maintenance; continued cardio-oncology surveillance (annual echo + GLS); ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting; oncology coordination for ongoing cancer care; dexrazoxane consideration if continued anthracycline therapy required (FDA-approved for metastatic breast cancer ≥300 mg/m² doxorubicin per Swain JCO 1997 PMID 9263800)
- Close-out criterion: Recovery echo + GLS + GDMT + ICD timeline + cardio-onc surveillance + oncology plan booked

Monitoring phase: A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q24h with LVEF + GLS for recovery trajectory; daily troponin + BNP; oncology coordination for cancer status; surveillance for late-effect arrhythmia in dilated chamber

Disposition

Current setting: outpatient — 4–8 wk recovery echo + GLS — confirm LV recovery (partial recovery 40–60% per Cardinale 2015); long-term GDMT 4-pillar; long-term cardio-oncology surveillance (annual echo + GLS); ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting; transplant evaluation if persistent severe LV dysfunction + cancer disease-free per modern criteria; oncology coordination for ongoing cancer surveillance + dexrazoxane consideration if continued anthracycline required per FDA label

Disposition criteria:
- Complete recovery (EF ≥55 + symptom-free + GLS recovered) → routine cardio-oncology surveillance
- Persistent HFrEF → long-term cross-link to cardio.hfref.core.v1 / cardio.hf.core.v1 with cardio-onc co-management

Escalation triggers (move to higher acuity):
- Sustained VT / syncope → EP urgent consult; consider catheter ablation; ICD
- Persistent severe LV dysfunction → transplant evaluation if cancer disease-free per modern criteria
- Cancer recurrence → oncology + cardio-onc joint decision on therapy choice (avoid further anthracycline if possible)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Refractory severe LV dysfunction with refractory shock in anthracycline-CMP — transplant evaluation despite cancer history; historical ISHLT 2016 disease-free interval ≥5 yr for solid tumors / ≥1 yr for hematologic being relaxed; case-by-case per modern criteria with cardio-onc + transplant + oncology MDT
- [LIFE_THREATENING] Sustained VT/VF or recurrent shocks within 24 h in dilated anthracycline-CMP — high arrhythmia risk in dilated chamber substrate; amiodarone + EP + escalate to MCS; ICD evaluation if cancer-prognosis permits
- [SEVERE] Cumulative doxorubicin >450 mg/m² (or daunorubicin >550, epirubicin >900) + new LVEF decline ≥10 absolute or to <50% — anthracycline cardiotoxicity confirmed; emergent oncology + cardio-onc decision to discontinue further anthracycline; consider dexrazoxane only if continued anthracycline benefit per FDA label (metastatic breast cancer)

Citations

- Lyon et al ESC 2022 cardio-oncology guideline (PMID 36017575); AHA 2022 cardio-oncology scientific statement; Cardinale et al JACC 2015 enalapril cardioprotection (PMID 25956652); Plana et al JASE/EACVI 2014 echo cardio-oncology consensus; Cardinale Circulation 2004 troponin early marker (PMID 15067104) [PMID:36017575](https://pubmed.ncbi.nlm.nih.gov/36017575/)
- Cited evidence (PMID 25956652) [PMID:25956652](https://pubmed.ncbi.nlm.nih.gov/25956652/)
- Cited evidence (PMID 15067104) [PMID:15067104](https://pubmed.ncbi.nlm.nih.gov/15067104/)
- Cited evidence (PMID 11248153) [PMID:11248153](https://pubmed.ncbi.nlm.nih.gov/11248153/)
- Cited evidence (PMID 9263800) [PMID:9263800](https://pubmed.ncbi.nlm.nih.gov/9263800/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Lyon et al ESC 2022 cardio-oncology guideline (PMID 36017575); AHA 2022 cardio-oncology scientific statement; Cardinale et al JACC 2015 enalapril cardioprotection (PMID 25956652); Plana et al JASE/EACVI 2014 echo cardio-oncology consensus; Cardinale Circulation 2004 troponin early marker (PMID 15067104) — PMID:36017575
  • Cited evidence (PMID 25956652) — PMID:25956652
  • Cited evidence (PMID 15067104) — PMID:15067104
  • Cited evidence (PMID 11248153) — PMID:11248153
  • Cited evidence (PMID 9263800) — PMID:9263800